"Calorie restriction induces mitochondrial biogenesis and bioenergetic efficiency." Proceedings of the National Academy of Sciences , 103(6), 17681773
Are you aware of any videos please
It remains an investigational drug currently being evaluated in Phase 3 clinical trials by Eli Lilly for the treatment of: Obesity (without diabetes) Type 2 diabetes Nonalcoholic fatty liver disease (NAFLD/NASH) Projected Approval Timeline Based on Phase 2 success and accelerated trials, Retatrutide could receive FDA approval as early as 2026 Eli Lilly is positioning it to directly compete with Tirzepatide (Mounjaro) and Semaglutide (Wegovy) Expected to be administered as a once-weekly injection Not Available for Research or Off-Label Use Retatrutide is not legally available on the gray market No legitimate research chemical suppliers offer it any listings claiming to sell Retatrutide are likely counterfeit or misbranded Because of its complex multi-receptor structure, DIY compounding is extremely risky and discouraged Athletic Use and WADA Considerations Like other GLP-1 agonists, Retatrutide is not currently banned by WADA However, its performance-enhancing effects (fat loss, appetite suppression, metabolic acceleration) could put it under scrutiny in the future Athletes in tested federations should proceed cautiously once the drug is commercialized Until Retatrutide clears regulatory approval, its use remains confined to clinical trial settings
Storage requirements Store your reconstituted vial upright in the refrigerator, away from the back wall (where it might freeze) and away from the door (where temperature fluctuates most)
BPC-157 and TB-500 are the two most commonly investigated synthetic peptides in preclinical tissue-repair research
While many clinics boast about their possible benefits for weight loss, note that very little research has examined the effects of lipotropic injections on weight loss
